Paradigm Health announced on March 20 the appointment of Karen E. Knudsen to its board of directors, alongside the upcoming launch of its eSource clinical trial data application.
The Association of Cancer Center Administrators presented its inaugural ACCA Career Achievement Award to Beverly Ginsburg Cooper, managing director at the Huron Consulting Group, on March 16. Given at the CCA Annual Business Meeting in Seattle, the ACCA Career Achievement Award recognizes current members of the Association of Cancer Center Administrators or former members of the Cancer Centers Administrators Forum who have demonstrated exemplary dedication, leadership, and lasting contributions to the field of cancer administration.
Jeffrey E. Lee was appointed chief medical executive at The University of Texas MD Anderson Cancer Center, effective April 1.
Michael Chan was appointed chair of Wake Forest University’s Department of Radiation Oncology, which he has led as interim chair since 2023. In his permanent role, he will advance the clinical, research and education missions of the department, while optimizing care delivery and clinical operations.
Walter J. “Wally” Curran, Jr. has been named the Whitaker Endowed Chief of Piedmont Oncology. This bestowed title is supported by the Piedmont Foundation’s Whitaker Endowment, a fund created by the Atlanta community in tribute to Piedmont’s cancer surgical leader, William Whitaker.
The Indiana University Melvin and Bren Simon Comprehensive Cancer Center has named John Turchi, the inaugural executive director of the Tom and Julie Wood Center for Lung Cancer Research.
Tracy Smith has joined Ashish Deshmukh as a co-leader of the Cancer Prevention and Control Research Program at MUSC Hollings Cancer Center.
The Cancer Research Institute is committing $2.5 million in reserve funding to support an additional postdoctoral fellowships in the face of federal instability.
In a prospective cohort study of more than 85,000 adults in the UK, researchers at the NIH and University of Oxford found that individuals who engaged in light- and moderate-to-vigorous-intensity daily physical activity had a lower risk of cancer than individuals who were more sedentary.
New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated non-small cell lung cancer. Highlights include:
